Alexey V. Danilov, MD, PhD

Articles

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

November 25th 2024

Drs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.

Dr Danilov on Ongoing MCL Clinical Trials

September 11th 2024

Alexey Danilov, MD, PhD, discusses ongoing investigations taking place to improve the treatment of patients with mantle cell lymphoma.

Clinical Pearls and Impacts to Practice from EHA 2024

September 5th 2024

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies

August 29th 2024

Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.

Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

August 29th 2024

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

Dr Danilov on Unmet Needs for Various CLL Subgroups

August 22nd 2024

Alexey Danilov, MD, PhD discusses unmet needs for patients with chronic lymphocytic leukemia.

Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

August 22nd 2024

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

August 22nd 2024

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices

August 15th 2024

Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.

Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice

August 15th 2024

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.

Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing

August 12th 2024

Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.

Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib

August 12th 2024

An oncology specialist outlines their general approach to managing treatment-related atrial fibrillation in patients receiving BTK inhibitor therapy, incorporating insights from recent clinical data to inform their management strategies.

Dr Danilov on the Importance of Using BTK as a Target in CLL Treatment

August 6th 2024

Alexey Danilov, MD, PhD, discusses the importance of using BTK as a target, as well as recent updates on BTK degraders within the CLL treatment paradigm.

Approach to Hypertension Management With BTKi Treatment

August 5th 2024

Medical experts deliberate on strategies for managing newly developed or exacerbated hypertension in patients undergoing treatment with BTK inhibitors for chronic lymphocytic leukemia.

Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities

August 5th 2024

Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.

BTKi Intolerance in Real-world Practice & Management Strategy

July 29th 2024

Key opinion leaders compare and contrast the most frequently observed causes of BTK inhibitor intolerance in clinical practice among patients treated with ibrutinib, acalabrutinib, or zanubrutinib.

How Experts View MAIC Data That was Presented at EHA 2024

July 29th 2024

A panel of experts examines and interprets the most recent matching-adjusted indirect comparison (MAIC) data presented at the European Hematology Association 2024 conference, focusing on the comparative analysis of the ASCEND and ALPINE trials in chronic lymphocytic leukemia treatment.

Navigating Treatment Approaches for R/R CLL

July 22nd 2024

A clinician outlines their treatment strategy for relapsed/refractory chronic lymphocytic leukemia patients, emphasizing how previous treatment history influences subsequent therapy choices.

EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches

July 22nd 2024

An expert in the field provides insights into current clinical trials investigating the efficacy of combined BCL-2 inhibitor and BTK inhibitor therapies.

Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL

July 15th 2024

Experts analyze the potential applications of triplet therapy (venetoclax, BTK inhibitor, and obinutuzumab) in first-line chronic lymphocytic leukemia treatment, focusing on patient subgroups most likely to benefit from this approach.